Preclinical studies using various breast cancer in vitro and in vivo models23–28 from our group identified a critical role for the most potent caspase inhibitor, X-linked inhibitor of apoptosis protein (XIAP), in linking EGFR-mediated MAPK activation and NFκB hyperactivity. Here, NFKB1 is linked to breast cancer.